QURE
Price
$17.95
Change
+$0.22 (+1.24%)
Updated
Sep 5 closing price
Capitalization
984.86M
53 days until earnings call
VRCA
Price
$5.11
Change
-$0.05 (-0.97%)
Updated
Sep 5 closing price
Capitalization
48.22M
65 days until earnings call
Interact to see
Advertisement

QURE vs VRCA

Header iconQURE vs VRCA Comparison
Open Charts QURE vs VRCABanner chart's image
uniQure
Price$17.95
Change+$0.22 (+1.24%)
Volume$2.08M
Capitalization984.86M
Verrica Pharmaceuticals
Price$5.11
Change-$0.05 (-0.97%)
Volume$32.79K
Capitalization48.22M
QURE vs VRCA Comparison Chart in %
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. VRCA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a StrongBuy and VRCA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (QURE: $17.95 vs. VRCA: $5.11)
Brand notoriety: QURE and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 189% vs. VRCA: 64%
Market capitalization -- QURE: $984.86M vs. VRCA: $48.22M
QURE [@Biotechnology] is valued at $984.86M. VRCA’s [@Biotechnology] market capitalization is $48.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, QURE is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 6 TA indicator(s) are bullish while VRCA’s TA Score has 2 bullish TA indicator(s).

  • QURE’s TA Score: 6 bullish, 4 bearish.
  • VRCA’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, QURE is a better buy in the short-term than VRCA.

Price Growth

QURE (@Biotechnology) experienced а +9.92% price change this week, while VRCA (@Biotechnology) price change was -8.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

QURE is expected to report earnings on Oct 29, 2025.

VRCA is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($985M) has a higher market cap than VRCA($48.2M). QURE YTD gains are higher at: 1.642 vs. VRCA (-27.071). VRCA has higher annual earnings (EBITDA): -38.54M vs. QURE (-119.56M). QURE has more cash in the bank: 377M vs. VRCA (15.4M). VRCA has less debt than QURE: VRCA (38.9M) vs QURE (66.7M). VRCA (14.7M) and QURE (14.3M) have equivalent revenues.
QUREVRCAQURE / VRCA
Capitalization985M48.2M2,044%
EBITDA-119.56M-38.54M310%
Gain YTD1.642-27.071-6%
P/E RatioN/AN/A-
Revenue14.3M14.7M97%
Total Cash377M15.4M2,448%
Total Debt66.7M38.9M171%
FUNDAMENTALS RATINGS
QURE vs VRCA: Fundamental Ratings
QURE
VRCA
OUTLOOK RATING
1..100
2760
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3687
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
48n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (77) in the Biotechnology industry is in the same range as VRCA (95) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to VRCA’s over the last 12 months.

QURE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to VRCA’s over the last 12 months.

QURE's SMR Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to VRCA’s over the last 12 months.

QURE's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for VRCA (87) in the Pharmaceuticals Major industry. This means that QURE’s stock grew somewhat faster than VRCA’s over the last 12 months.

QURE's P/E Growth Rating (91) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QUREVRCA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 26 days ago
86%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCIUX11.86N/A
N/A
Invesco Income Advantage U.S. Fund R5
TGFRX54.46N/A
N/A
Tanaka Growth
RLECX21.76N/A
N/A
Russell Inv US Small Cap Equity C
FCIGX35.08N/A
N/A
Fidelity Advisor Small Cap Growth I
CMGVX32.57N/A
N/A
Columbia Select Mid Cap Gro Fd I2

VRCA and

Correlation & Price change

A.I.dvisor tells us that VRCA and ACOG have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VRCA and ACOG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
-1.07%
ACOG - VRCA
31%
Poorly correlated
+6.59%
PBYI - VRCA
30%
Poorly correlated
-1.57%
SLNO - VRCA
29%
Poorly correlated
+0.29%
FGEN - VRCA
29%
Poorly correlated
+6.98%
QURE - VRCA
27%
Poorly correlated
+1.24%
More